Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

RANDOMIZED PHASE II TRIAL EVALUATING THE ADDITION OF THE IGF-1R MONOCLONAL ANTIBODY GANITUMAB (AMG 479, NSC#750008, IND#120449) TO MULTIAGENT CHEMOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED METASTATIC EWING SARCOMA

Intervention/treatment:
AMG 479 (GANITUMAB)/PROCYTOX (CYCLOPHOSPHAMIDE)/ZINECARD (DEXRAZOXANE)/VEPESID (ETOPOSIDE)/ETOPOPHOS (ETOPOSIDE PHOSPHATE)/IFEX (IFOSFAMIDE)/18-FDG ([18F]-FLUORODEOXYGLUCOSE)
Medical condition:
SARCOMA
Protocol code:
COG AEWS1221
Control number:
182190
Status:
Active, not recruiting
Approved:
March 19, 2015
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT02306161
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
Birth to 50 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Results Reporting Coordinator
Organization
Children's Oncology Group
Phone:
16264470064
Sponsor
CHILDRENS ONCOLOGY GROUP

Locations

CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
Québec, G1V 4G2

Alberta

Alberta Children's Hospital
Calgary, Alberta, T3B 6A8
University of Alberta Hospital
Edmonton, Alberta, T6G 2B7

British Columbia

British Columbia Children's Hospital
Vancouver, British Columbia, V6H 3V4

Manitoba

CancerCare Manitoba
Winnipeg, Manitoba, R3E 0V9

Newfoundland and Labrador

Janeway Child Health Centre
St. John's, Newfoundland and Labrador, A1B 3V6

Nova Scotia

IWK Health Centre
Halifax, Nova Scotia, B3K 6R8

Ontario

Children's Hospital
London, Ontario, N6A 5W9
Children's Hospital of Eastern Ontario
Ottawa, Ontario, K1H 8L1
Hospital for Sick Children
Toronto, Ontario, M5G 1X8
Kingston Health Sciences Centre
Kingston, Ontario, K7L 2V7
McMaster Children's Hospital at Hamilton Health Sciences
Hamilton, Ontario, L8N 3Z5

Quebec

Centre Hospitalier Universitaire Sainte-Justine
Montreal, Quebec, H3T 1C5
The Montreal Children's Hospital of the MUHC
Montreal, Quebec, H3H 1P3

Results

See the results from the trial NCT02306161. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?